Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6532 dose-ranging phase 3 trial in uncontrolled severe eosinophilic asthma
2018-003548-22Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of timapiprant in eosinophilic asthma (EA) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Rate of moderate and severe asthma exacerbation over 52 weeks of treatment. Started Feb 2019; status: completed.
02
Drugs
timapiprant
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2018-003548-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003548-22.